The Public Health Emergency Medical Countermeasures Enterprise Innovative Strategies to Enhance Products from Discovery Through Approval Workshop Summary Theresa Wizemann, Clare Stroud, and Bruce M Altevogt, Rapporteurs Forum on Medical and Public Health Preparedness for Catastrophic Events Forum on Drug Discovery, Development, and Translation Board on Health Sciences Policy THE NATIONAL ACADEMIES PRESS • 500 Fifth Street, N.W • Washington, DC 20001 NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine The members of the committee responsible for the report were chosen for their special competences and with regard for appropriate balance This project was supported by contracts between the National Academy of Sciences and the American College of Emergency Physicians, the American Hospital Association, the American Medical Association, the American Nurses Association, the Association of State and Territorial Health Officials, the Centers for Disease Control and Prevention (Contract No 200-2005-13434 TO #6), the Department of the Army (Contract No W81XWH-08-P-0934), the Department of Health and Human Services’ Agency for Healthcare Research and Quality (Contract No HHSP233200800498P), the Department of Health and Human Services’ National Institutes of Health (Contract No N01-OD-42139 TO #198), the Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (Contract Nos HHSP233200900680P, HH5P23320042509X1), the Department of Homeland Security’s Office of Health Affairs (Contract No HSHQDC-07-C-00097), the Department of Homeland Security’s Federal Emergency Management Agency (Contract No HSFEHQ-08-P-1800), the Department of Veterans Affairs (Contract No V101(93)P-2136 TO #10), the Emergency Nurses Association, the National Association of Chain Drug Stores, the National Association of County and City Health Officials, the National Association of Emergency Medical Technicians, the Pharmaceutical Research and Manufacturers of America, The Robert Wood Johnson Foundation, and the United Health Foundation The views presented in this publication are those of the editors and attributing authors and not necessarily reflect the views of the organizations or agencies that provided support for this project International Standard Book Number-13: 978-0-309-15024-8 International Standard Book Number-10: 0-309-15024-8 Additional copies of this report are available from The National Academies Press, 500 Fifth Street, N.W., Lockbox 285, Washington, DC 20055; (800) 624-6242 or (202) 3343313 (in the Washington metropolitan area); Internet, http://www.nap.edu For more information about the Institute of Medicine, visit the IOM home page at: www.iom.edu Copyright 2010 by the National Academy of Sciences All rights reserved Printed in the United States of America Suggested citation: IOM (Institute of Medicine) 2010 The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary Washington, DC: The National Academies Press The National Academy of Sciences is a private, nonprofit, self-perpetuating society of distinguished scholars engaged in scientific and engineering research, dedicated to the furtherance of science and technology and to their use for the general welfare Upon the authority of the charter granted to it by the Congress in 1863, the Academy has a mandate that requires it to advise the federal government on scientific and technical matters Dr Ralph J Cicerone is president of the National Academy of Sciences The National Academy of Engineering was established in 1964, under the charter of the National Academy of Sciences, as a parallel organization of outstanding engineers It is autonomous in its administration and in the selection of its members, sharing with the National Academy of Sciences the responsibility for advising the federal government The National Academy of Engineering also sponsors engineering programs aimed at meeting national needs, encourages education and research, and recognizes the superior achievements of engineers Dr Charles M Vest is president of the National Academy of Engineering The Institute of Medicine was established in 1970 by the National Academy of Sciences to secure the services of eminent members of appropriate professions in the examination of policy matters pertaining to the health of the public The Institute acts under the responsibility given to the National Academy of Sciences by its congressional charter to be an adviser to the federal government and, upon its own initiative, to identify issues of medical care, research, and education Dr Harvey V Fineberg is president of the Institute of Medicine The National Research Council was organized by the National Academy of Sciences in 1916 to associate the broad community of science and technology with the Academy’s purposes of furthering knowledge and advising the federal government Functioning in accordance with general policies determined by the Academy, the Council has become the principal operating agency of both the National Academy of Sciences and the National Academy of Engineering in providing services to the government, the public, and the scientific and engineering communities The Council is administered jointly by both Academies and the Institute of Medicine Dr Ralph J Cicerone and Dr Charles M Vest are chair and vice chair, respectively, of the National Research Council www.national-academies.org Workshop Planning Committee* GAIL CASSELL (Chair), Eli Lilly and Company, Indianapolis, IN PHYLLIS ARTHUR, Biotechnology Industry Organization, Washington, DC CAPTAIN KENNETH COLE, Office of Assistant Secretary of Defense for Health Affairs, Department of Defense, Washington, DC ALEXANDER GARZA, Department of Homeland Security, Washington, DC JOHN GRABENSTEIN, Merck & Co., Inc., Whitehouse Station, NJ ELIN GURSKY, Analytic Services Inc., Arlington, VA TIL JOLLY, Department of Homeland Security, Washington, DC ROBERT KADLEC, PRTM Management Consultants, Washington, DC GEORGE KORCH, Department of Health and Human Services, Washington, DC MICHAEL KURILLA, National Institute of Allergy and Infectious Diseases, Bethesda, MD NICOLE LURIE, Department of Health and Human Services, Washington, DC BORIS LUSHNIAK, Food and Drug Administration, Rockville, MD MONIQUE MANSOURA, Department of Health and Human Services, Washington, DC PETER PALESE, Mount Sinai School of Medicine, New York RON SALDARINI, Biological Initiatives, Mahwah, NJ DANIEL SOSIN, Centers for Disease Control and Prevention, Atlanta, GA JANET TOBIAS, Ikana Media, New York ERIC TONER, University of Pittsburgh, Pittsburgh, PA STEPHANIE ZAZA, Centers for Disease Control and Prevention, Atlanta, GA ∗ IOM planning committees are solely responsible for organizing the workshop, identifying topics, and choosing speakers The responsibility for the published workshop summary rests with the workshop rapporteurs and the institution v IOM Staff BRUCE ALTEVOGT, Preparedness Forum Director ROBERT GIFFIN, Drug Forum Director (until March 2010) CLARE STROUD, Program Officer ANDREW POPE, Director, Board on Health Sciences Policy AMY PACKMAN, Administrative Assistant ALEX REPACE, Senior Program Assistant vi Forum on Medical and Public Health Preparedness for Catastrophic Events* LEWIS GOLDFRANK (Chair), New York University Medical Center, New York DAMON ARNOLD, Association of State and Territorial Health Officials, Arlington, VA GEORGES BENJAMIN, American Public Health Association, Washington, DC D W CHEN, Office of Assistant Secretary of Defense for Health Affairs, Department of Defense, Washington, DC ROBERT DARLING, Uniformed Services University, Bethesda, MD VICTORIA DAVEY, Department of Veterans Affairs, Washington, DC JEFFREY DUCHIN, Seattle & King County and University of Washington, Seattle ALEXANDER GARZA, Department of Homeland Security, Washington, DC LYNN GOLDMAN, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD DAVID HENRY, National Governors Association, Washington, DC JACK HERRMANN, National Association of County and City Health Officials, Washington, DC KEITH HOLTERMANN, Federal Emergency Management Agency, Washington, DC JAMES JAMES, American Medical Association, Chicago, IL JERRY JOHNSTON, National Association of Emergency Medical Technicians, Mt Pleasant, IA ROBERT KADLEC, PRTM Management Consultants, Washington, DC BRIAN KAMOIE, The White House, Washington, DC LYNNE KIDDER, Business Executives for National Security, Washington, DC MICHAEL KURILLA, National Institute of Allergy and Infectious Diseases, Bethesda, MD * IOM forums and roundtables not issue, review, or approve individual documents The responsibility for the published workshop summary rests with the workshop rapporteurs and the institution vii JAYNE LUX, National Business Group on Health, Washington, DC ANTHONY MACINTYRE, American College of Emergency Physicians, Washington, DC ANGELA MCGOWAN, Robert Wood Johnson Foundation, Princeton, NJ MARGARET MCMAHON, Emergency Nurses Association, Williamstown, NJ ERIN MULLEN, Pharmaceutical Research and Manufacturers of America, Washington, DC GERALD PARKER, Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services, Washington, DC CHERYL PETERSON, American Nurses Association, Silver Spring, MD SALLY PHILLIPS, Agency for Healthcare Research and Quality, Rockville, MD STEVEN PHILLIPS, National Library of Medicine, Bethesda, MD EDITH ROSATO, National Association of Chain Drug Stores Foundation, Alexandria, VA (since July 2009) PHILLIP SCHNEIDER, National Association of Chain Drug Stores Foundation, Alexandria, VA (until July 2009) ROSLYNE SCHULMAN, American Hospital Association, Washington, DC DANIEL SOSIN, Centers for Disease Control and Prevention, Atlanta, GA SHARON STANLEY, American Red Cross, Washington, DC ERIC TONER, University of Pittsburgh Medical Center, Pittsburgh, PA REED TUCKSON, UnitedHealth Group, Minneapolis, MN MARGARET VANAMRINGE, The Joint Commission, Washington, DC IOM Staff BRUCE ALTEVOGT, Project Director CLARE STROUD, Program Officer ANDREW POPE, Director, Board on Health Sciences Policy ALEX REPACE, Senior Program Assistant viii Forum on Drug Discovery, Development, and Translation* GAIL CASSELL (Co-Chair), Eli Lilly and Company, Indianapolis, IN JEFFREY DRAZEN (Co-Chair), New England Journal of Medicine, Boston, MA BARBARA ALVING, National Center for Research Resources, Bethesda, MD LESLIE BENET, University of California–San Francisco, CA ANN BONHAM, Association of American Medical Colleges, Washington, DC LINDA BRADY, National Institute of Mental Health, Bethesda, MD ROBERT CALIFF, Duke University Medical Center, Durham, NC SCOTT CAMPBELL, American Diabetes Association, Alexandria, VA THOMAS CASKEY, University of Texas HSC at Houston, Texas PETER CORR, Celtics Therapeutics LLLP, New York JAMES H DOROSHOW, National Cancer Institute, Bethesda, MD PAUL EISENBERG, Amgen, Inc., Thousand Oaks, CA GARY FILERMAN, ATLAS Research, Washington, DC GARRET FITZGERALD, University of Pennsylvania School of Medicine, Philadelphia, PA ELAINE GALLIN, The Doris Duke Charitable Foundation, New York STEVEN GALSON, Science Operation International Corporation, Rockville, MD HARRY GREENBERG, Stanford University School of Medicine, Stanford, CA STEPHEN GROFT, Office of Rare Disease Research, National Institutes of Health, Bethesda, MD PETER HONIG, Merck & Co., Inc (Retired), Collegeville, PA ANNALISA JENKINS, Bristol Myers Squibb, Plainsboro, NJ MICHAEL KATZ, March of Dimes Foundation, New York JACK KEENE, Duke University Medical Center, Durham, NC RONALD KRALL, GlaxoSmithKline (Retired), Steamboat Springs, CO * IOM forums and roundtables not issue, review, or approve individual documents The responsibility for the published workshop summary rests with the workshop rapporteurs and the institution ix 166 EMERGENCY MEDICAL COUNTERMEASURES ENTERPRISE CONCLUSIONS AND PATH FORWARD Selection of Incentives Interview and document findings suggest the following conclusions regarding potential incentives that could be applied to the MCM business model: • • • • • • Pull strategies that increase market sustainability might be more effective than push strategies One industry interviewee echoed the feeling of many that “the most important incentives are the ones that get us to a market- to product sales.” Push strategies should focus on “opening the door to partnerships between companies.” No one push or pull incentive will be sufficient to attract companies to the MCME Combinations of push and pull incentives may be sufficient, dependent upon on policy and strategy decisions for each MCM program and on the maturity of the pipelines No one combination of incentives is the “right” model The effectiveness of different incentives depends on context of policies, products, and players Minimizing disincentives may be enough to “tip the scale” and would “send a signal that the MCME is committed to collaborating with industry.” Most Frequently Cited Opportunities for Increasing Participation Under the current policy of focusing on post-event response based on stockpiled product, opportunities to increase industry participation exist across the latter three segments of the MCME Business Model Framework Based on the literature review and the perspectives of SMEs collected throughout interviews, we provide below a summary of the most frequently cited opportunities for increasing the level and mix of involvement by pharmaceutical and biotechnology companies the MCME APPENDIX E 167 These opportunities assume a continued policy of focusing on postevent response based on stockpiled product Alternative policies could have a cascade of alternate approaches Policies For Product Use Product Strategies Players and Roles Push and Pull Incentives FIGURE E-4 Opportunities for inducing industry participation stem from product strategies, players and roles, and push and pull incentives Product Strategies: To date the pursuit, broad-spectrum approaches within the MCME product strategy have been limited Successful efforts have primarily been constrained to new indications for antibiotics In order to expand into the range of competitive returns for industry, it will be necessary to increase the emphasis placed on dual-use products, platforms, and technologies with commercial applications Examples of this product strategy include vaccine platforms and multiple indications on a single drug product Players and Roles: To date, the MCME’s business model has primarily attracted innovator companies to manage the entire development chain, from early stage discovery research through late stage development and production A more effective approach may be to focus on taking advantage of the strengths of a broader set of industry players Specifically, the USG should look to innovator companies to drive products through proof of concept, while relying on larger, more experienced companies for late-stage development and manufacturing This division of labor caters to the strengths and risk profiles of each group To that end, the USG and MCME leaders should explore opportunities to promote partnering throughout the enterprise landscape The concept of partnerships, in multiple forms, was consistently recommended by stakeholders and subject matter experts we interviewed Incentives: A variety of potential incentives were explored throughout the literature and stakeholder interviews The single most critical factor in the eyes of the experts we surveyed was that the USG must demonstrate a reliable, long-term market for MCM products Whether accomplished by increasing/extending BioShield, or through some other approach, establishing market credibility is pivotal in positioning MCME projects for serious consideration by industry 168 EMERGENCY MEDICAL COUNTERMEASURES ENTERPRISE Additional incentives that drew significant attention and favor among the interview candidates and literature authors include the following: • • • Priority Review Vouchers—PRV’s appeal to a broad range of stakeholders because they represent an incentive that could be highly valued by industry while carrying limited social cost Tax incentives—This tool could be particularly effective if structured such that larger companies that partner with innovator companies earn a valuable tax credit Such an incentive would promote the partnerships noted in the previous section as a powerful approach to development Additional Funding—Biopharmaceutical research is expensive With $5.6 billion allocated over 10 years to purchase at least 14 CBRN threat agents, BioShield is unlikely to draw participation from large, pharmaceutical companies 102 No matter how funds are shared among push and pull mechanisms targeted at pharmaceutical companies for MCM research, it is unlikely that $900 million dispersed among various incentives would appear more attractive to industry than a $3 billion commercial drug 103 APPENDIXES Examples of Incentive Structures from Other Sectors Renewable Energy • • • 102 103 Goal: Encourage and increase adoption of renewable energy sources despite higher costs/risks to suppliers Incentives: Guaranteed capacity, risk reduction, and adjusted compensation Relevance: Similar to MCME’s high opportunity cost and expensive manufacturing processes Matheny et al., 2007 Ibid APPENDIX E 169 Commercial Space Launch • • • Goal: Attract first rate talent and technology to an extremely high risk/high cost industry Incentives: Prizes, pay-for-performance, leverageable capital investments Relevance: Similar to MCME’s “lumpy” revenue streams, long lead times, exclusive government market Defense • • • Goal: Encourage industry to support a market that is almost exclusively government driven; encouraging production and capacity investment during difficult economies Incentives: Demand aggregation, purchase commitments, subsidies, knowledge sharing Relevance: Mirrors MCME’s need for multiple incentive approaches Semiconductors • • • Goal: Generate rapid innovation and advancement in U.S semiconductor industry to reclaim lost market share Incentives: Trade agreements, public–private partnership (SEMATECH) Relevance: Provides excellent model of public–private partnership success Nuclear Technologies • • • Goal: Stimulate interest in the nuclear power industry where liability, in the case of a nuclear accident, was a serious obstacle Incentives: Liability protection through the Price Anderson Act, which provided more than $9.5B in insurance coverage Relevance: Like MCME, concern over indemnification hinders industry participation Biotechnology Incubators • Goal: Foster growth of innovative technologies and ideas from startup ventures who cannot reach commercialization alone 170 • • EMERGENCY MEDICAL COUNTERMEASURES ENTERPRISE Relevance: Provide services in line with needs of inexperienced biodefense companies Incentives: Provide services to expedite R&D of promising biotechnologies BIBLIOGRAPHY AdvancedMarkets Working Group 2005 (April 7) Making markets for vaccines Center for Global Development Andre, F E 2002 How the research-based industry approaches vaccine development and establishes priorities Developments in Biologicals 110:25-29 Audretsch, D B., B Bozeman, K L Combs et al 2002 The economics of science and technology Journal of Technology Transfer 27:155-203 Baker, D 2004 (Sept 22) Financing drug research: What are the issues? Center for Economic and Policy Research BARDA Authorities Assessment 2008 (Sept 12) HHS Transition Package Berndt, E., and J Hurvitz 2005 Vaccine advance-purchase agreements for low-income countries: Practical issues Health Affairs 24(3):653-665 Berndt, E., et al (incl R Levine) 2006 (Aug.) Advance market commitments for vaccines against neglected diseases: Estimating costs and effectiveness Center for Global Development Working Paper No 98 Brogan, D., and E Mossialos 2006 (Aug.) Applying the concepts of financial options to stimulate vaccine development Nature Reviews Drug Discovery 5:641-647 Challenge and Opportunity on the Critical Path to New Medical Products 2004 (March) FDA Critical Path Initiative Chesbrough, H 2003 Open innovation: The new imperative for creating and profiting from technology Harvard Business School Publishing Company APPENDIX E 171 Commercial Spaceflight Federation 2009 (June 29) Commercial spaceflight in low earth orbit is the key to affordable and sustainable exploration beyond Input into the Review of U.S Human Space Flight Plans Committee Critical Path Opportunities Report 2006 (March) FDA Critical Path Initiative CSC News Release 2008 (June 5) CSC’s DynPort Vaccine Company to continue plague vaccine development DARPA Grand Challenge Website (accessed March 7, 2010) DiMasi, J A., and H G Grabowski 2007 The cost of biopharmaceutical R&D: Is biotech different? Managerial and Decision Economics 28:469-479 DiMasi, J., et al 2010 (Feb 3) Trends in risks associated with new drug development: Success rates for investigational drugs Nature Publishing Group: Clinical Pharmacology and Therapeutics Doremus, P 2008 (July 17) The R&E tax credit: Rationale, structure and performance The National Institute of Standards and Technology, Strategic Planning & Economic Analysis Group Fuerst, T et al 2009 Ensuring biologics advanced development and manufacturing capability for the United States Government—A summary of key findings and conclusions Pittsburgh, PA: UPMC GAVI Presentation Accelerating the development and use of new vaccines: Economic and financial incentives GAVI Press Release 2009 (Oct 12) Update: Pneumococcal AMC receives four offers from vaccine manufacturers http://www.vaccineamc.org/ updateoct12_09.html Global Health Security Initiative Website 2010 (accessed March 7, 2010) 172 EMERGENCY MEDICAL COUNTERMEASURES ENTERPRISE Global Security Newswire 2010 (Feb 26) Former HHS official backs home kits for biodefense Gottron, F 2007 (June 11) Project BioShield: Appropriations, acquisitions, and policy implementation issues for Congress Washington, DC: Congressional Research Service Gottron, F., and E Fisher 2004 (Aug 27) Project BioShield: Legislative history and side-by-side comparison of H.R 2122, S 15, and S 1504 Washington, DC: Congressional Research Service Grabowski, H 2005 (May/June) Encouraging the development of new vaccines Health Affairs 24(3):697-700 Grabowski, H 2005 Increasing R&D incentives for neglected diseases: Lessons from the Orphan Drug Act In Cambridge University Press conference volume, edited by J Reichman Pp 457-480 Grabowski, H., D Ridley, and J Moe 2009 Encouraging innovative treatment of neglected diseases through Priority Review Vouchers Prescribing Cultures and Pharmaceutical Policy in the Asia-Pacific Pp 347-365 Gronvall, G., et al on behalf of the Alliance for Biosecurity 2007 The FDA Animal Efficacy Rule and biodefense Nature Biotechnology Guidance for Industry: Animal models—Essential elements to address efficacy under the Animal Rule 2009 (Jan.) HHS, FA, CDER, CBER Hatchett, R 2009 (Oct 27) Alternative models for medical countermeasures development HHS PHEMCE stakeholders workshop 2007 report 2008 (July/Aug.) Biomedical Advanced Research and Development Authority Higgins, M., and S Graham 2009 (Oct.) Balancing innovation and access: Patent challenges tip the scales Science 326(5951):370-371 Hsu, J., and E Schwartz 2003 (Oct.) A model of R&D valuation and the design of research incentives NBER Working Paper 10041 APPENDIX E 173 Hu et al 2007 (March 12) The innovation gap in pharmaceutical drug discovery and new models for R&D success Kellogg School of Management Inglesby, T 2008 Building an effective government–private sector partnership for biodefense PHEMCE Stakeholders Workshop IOM (Institute of Medicine) 2002 Protecting our forces: Improving vaccine acquisition and availability in the U.S military Washington, DC: The National Academies Press IOM 2004 Giving full measure to countermeasures: Addressing problems in the DoD program to develop medical countermeasures against biological warfare agents Washington, DC: The National Academies Press IOM 2008 Addressing the barriers to pediatric drug development: Workshop summary Washington, DC: The National Academies Press IOM 2009 Breakthrough business Models: Drug development for rare and neglected diseases and individualized therapies Washington, DC: The National Academies Press IOM 2010 (Feb.) The Public Health Emergency Medical Countermeasures Enterprise: Innovative strategies to enhance products from discovery through approval An Institute of Medicine Workshop Klotz, L C., and A Pearson A 2009 BARDA’s budget Nat Biotechnol 27(8):698-699; author reply 699 Kremer, M 2000 (May 24) Creating markets for new vaccines, Part 1: Rationale The Brookings Institute and NBER Kremer, M 2000 (May 24) Creating Markets for New Vaccines Harvard University, Brookings Institute, and NBER Lightfoot, N 2009 (Nov.) The Global Health Security Initiative (GHSI) Public Health Emergency Medical Countermeasures (MCM) Workshop U.S Department of Health and Human Services LINUX Website (accessed March 7, 2010) 174 EMERGENCY MEDICAL COUNTERMEASURES ENTERPRISE Matheny, J., et al 2006 Drug and vaccine development for infectious diseases: The value of Priority Review Vouchers Clinical Pharmacology and Therapeutics 85(6):571-572 Matheny, J., et al 2007 Incentives for biodefense countermeasure development Biosecur Bioterror 5(3):228-238 Matheny, J., M Mair, and B Smith 2008 Cost/success projections for US biodefense countermeasure development Nat Biotechnol 26(9):981983 Maurer, S 2005 The right tools: Designing cost-effective strategies for neglected disease research Goldman School of Public Policy, University of California–Berkeley Maurer, S 2009 Squeezing value from Homeland Security research: Designing better R&D incentives In WMD Terrorism: Science and Policy Choices The MIT Press McKenna, F 2009 (July 20) Commercial launch faces economic reality, again From International Launch Services Space News Merck Newsroom 2009 (Dec 27) Merck & Co to acquire Avecia Biologics Milken Institute 2006 (Oct.) Financial innovations for accelerating medical solutions Milken Institute Publication Monath, T Developing products against biological and emerging threats: Progress, pitfalls and set-backs KPCB Presentation Moran, M 2005 A breakthrough in R&D for neglected diseases: New ways to get the drugs we need PLoS Medicine 2(9):0828-0832 Moran, M 2006 (Sept.) The new landscape of neglected disease drug development Medicines for Malaria Venture Munos, B 2006 (Aug 18) Can open-source R&D reinvigorate drug research? Nature Reviews Drug Discovery; Perspectives APPENDIX E 175 Munos, B 2009 Lessons from 60 years of pharmaceutical innovation Nature Reviews Drug Discovery pp 959-968 Munos, B., and W Chin 2009 (Dec.) A call for sharing: Adapting pharmaceutical research to new realities Science Translational Medicine 1(9) Optimizing industrial involvement with medical countermeasure development: A report of the National Biodefense Science Board 2010 (Feb.) Department of Health and Human Services Orphan Drug Act 1983 Public Law 97-414 Parker, G 2007 HHS Public Health Emergency Medical Countermeasures Enterprise implementation plan for chemical, biological, radiological and nuclear Threats Federal Register 72(77):20117-20128 PHEMCE Strategy and Implementation Plan 2007 Department of Health and Human Services, Assistant Secretary for Emergency and Preparedness Response PHEMCE Workshop 2008 & BARDA Industry Day Report 2008 (September) Biomedical Advanced Research and Development Authority Plahte, J 2005 (Jan.) Tiered pricing of vaccines: A win-win-win situation, not a subsidy Lancet Infect Dis 5:58-63 Radcliffe, S 2008 Strategies and suggestions: Developing and sustaining a biodefense industry PHEMCE Stakeholders Workshop Report on Biological Warfare Defense Vaccine Research & Development Programs (Top Report) 2001 Department of Defense S 3678: Pandemic and All-Hazards Preparedness Act 2005-06 109th Congress Scannon, P 2008 (June) A realistic path to future medical countermeasure development and acquisition for the Strategic National Stockpile 176 EMERGENCY MEDICAL COUNTERMEASURES ENTERPRISE Scannon, P 2008 Strategies and suggestions for developing and sustaining a biodefense industry: A focus on medical countermeasures PHEMCE Stakeholders Workshop Schacht, W 2005 (May 6) Bioterrorism countermeasure development: Issues in patents and homeland security CRS Report to Congress Schacht, W., and J Thomas 2007 Bioterrorism countermeasure development: Issues in patents and homeland security Washington, DC: Congressional Research Service Schoonmaker, M 2005 (March 9) From bench to bedside: The role of Health and Human Services (HHS) in the evaluation of new medical products CRS Report to Congress Touse, A., and H Kettler 2004 (March 9) Advance price or purchase commitments to create markets for treatment for diseases of poverty: Lessons from three policies Bulletin of the World Health Organization 84(4) Tucker, J 2009 Developing medical countermeasures: From BioShield to BARDA Drug Development Research 70(4):224-233 White House’s Homeland Security Presidential Directive 18 2007 (Feb 7) White House Office of the Press Secretary Witty, A 2010 (Jan.) Open labs, open minds: Breaking down barriers to innovation and access to medicines and vaccines in the developing world From GlaxoSmithKline—Remarks delivered to the Council on Foreign Relations, New York Zerhouni, E 2009 (Dec.) Peer-to-peer sharing spurs scientific innovation Science Translational Medicine APPENDIX E 177 LIST OF INTERVIEWS The following is a list of individuals who were interviewed by PRTM for the purpose of this White Paper Affiliations listed reflect the individuals primary association as of the date of the interview Jennifer B Alton, Bavarian-Nordic Marguerite Baxter, Novartis Ernst Berndt, MIT Sloan School of Management Luciana Borio, HHS/FDA Carla Botting, Malaria Vaccine Initiative Mike Callahan, DARPA Francesca Cook, PharmAthene Jodie Curtis, Alliance Secretariat Jeffrey Fu, Merck Thomas Fuerst, HHS/ASPR/BARDA John Grabenstein, Merck; National Biodefense Science Board Henry G Grabowski, Duke University Maureen Hardwick, Alliance for Biosecurity Richard Hatchett, HHS/NIH/The White House Robert House, DynPort Vaccine Company Gerry Kovacs, HHS/ASPR/BARDA Michael Kurilla, HHS/NIH Carol Linden, HHS/ASPR/BARDA Boris D Lushniak, HHS/FDA Ronald Manning, HHS/ASPR/BARDA Jerry Middleton, Elusys Therapeutics Thomas P Monath, Kleiner Perkins Caufield & Byers Bernard Munos, Eli Lilly David Noll, Bavarian-Nordic Linda Nyari, PATH Joanna Prasher, HHS/ASPR/BARDA Rino Rappuoli, Novartis 178 EMERGENCY MEDICAL COUNTERMEASURES ENTERPRISE John H Rex, AstraZeneca David Ridley, Duke University Robin Robinson, HHS/ASPR/BARDA Eric Rose, Siga Technologies Phillip Russell, Sabin Vaccine Institute Jerry Sadoff, AERAS Patrick J Scannon, Xoma; National Biodefense Science Board Bradley Smith, UPMC Center for Biosecurity CONTACT INFORMATION Michael Mair, MPH Program Analyst Policy, Planning, and Requirements Division Office of the Assistant Secretary for Preparedness and Response Department of Health and Human Services Michael.Mair@hhs.gov 202-260-1343 James Guyton Principal PRTM Management Consultants, LLC 1750 Pennsylvania Avenue NW Suite 1000 Washington, DC 20006 jguyton@prtm.com 410-428-3259 Hannah McClellan Associate PRTM Management Consultants, LLC 1750 Pennsylvania Avenue NW Suite 1000 Washington, DC 20006 hmcclellan@prtm.com 617-680-4500 APPENDIX E Fanni Li Consultant PRTM Management Consultants, LLC 1750 Pennsylvania Avenue NW Suite 1000 Washington, DC 20006 fli@prtm.com 781-526-8191 179 ... Medicine) 2010 The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval: Workshop Summary Washington, DC: The National... 2010, titled The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery Through Approval The workshop was designed to examine federal.. .The Public Health Emergency Medical Countermeasures Enterprise Innovative Strategies to Enhance Products from Discovery Through Approval Workshop Summary Theresa Wizemann, Clare